QPS Launches New Leukopak and Cell Therapy Products Facility
QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. QPS is a full service CRO that’s dedicated to supporting drug development from conceptualization through to commercial launch. This facility is providing critical raw materials for the research and development of cell therapies but will soon be supporting clinical and commercial cell therapy companies and patients. In addition, this new facility will support the local economy by providing stipends to blood product donors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113328476/en/
The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)
To build out the facility and ensure the success of this new venture, QPS has hired Tia Hexom, PhD, (Senior Director of Cell Therapy Services and Manufacturing). With over a decade of experience in the cell therapy field, Hexom is excited to be building cell therapy capabilities in the Midwestern United States.
QPS Missouri is a division of QPS Holdings LLC, a global Clinical Research Organization (CRO) that conducts studies on behalf of pharmaceutical and biotech companies for the development of new and existing pharmaceutical products. This new Leukopak and Cell Therapy products donation and processing center will be housed in the same building as the new, state-of-the-art Screening and Recruitment Center that opened in July 2022, located at 2025 W. Sunshine Street, Springfield, MO. Study participants and blood product donors are paid a stipend for their participation in these Clinical Research activities. These stipends benefit the study participants and donors and, therefore, the local economy.
“Our participants and donors are a key part of the success of QPS in Springfield, Missouri and they continue to make a difference by helping advance drug development research,” states Brendon Bourg, Vice President, Early Phase Clinical/Head of Administration QPS Missouri. “To have the opportunity and ability to provide this type of supplemental income to our local community, while providing a valuable service to our pharmaceutical and biotech clients is something we (QPS) are honored to be a part of.”
Located in Springfield, QPS Missouri has been conducting clinical research studies for over 30 years, with the help of more than 50,000 study participants. In addition to the new Cell Therapy facilities, the Springfield campus houses five independent clinics with more than 240 beds, a pharmacy with a retention area, local and central CAP/CLIA safety lab, a clinical trial kit processing area, and a 2,500 square foot negative pressure room.
QPS has always been on the front line of clinical research in all areas of pharmaceutical and biotech drug development. Since opening its doors in Springfield in 1994, QPS Missouri has conducted more than 2,000 Phase I FDA-regulated studies and paid over $50 million to local participants and donors.
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products (such as Leukopaks and PBMCs), clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I clinical facilities, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113328476/en/
Contacts
Gabrielle Pastore, QPS Marketing
Phone: 302-287-7821
Email: gabrielle.pastore@qps.com
Website: www.qps.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qps.com&esh
eet=54151703&newsitemid=20241113328476&lan=en-US&anchor=www.qps.com&index=2&md5=
8586b94df60fd6abd834882cd1e26b64
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Announces Rimini Protect ™ Advanced Hypervisor Security for VMware, Nutanix and All Other Linux-Based Hypervisors, Powered by Vali Cyber ® , to Safeguard Against Ransomware and Other Vulnerabilities22.1.2025 15:00:00 CET | Press Release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, the leading third-party support provider for Oracle, SAP and VMware software, today announced the general availability of Rimini Protect™ Advanced Hypervisor Security (AHS), an exclusive solution powered by proven Vali Cyber® AI/ML security technology. The Rimini Protect AHS solution leverages these innovative capabilities that are already protecting mission-critical hypervisor infrastructure, including US military VMware deployments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122401764/en/ Rimini Street Announces Rimini Protect™ Advanced Hypervisor Security for VMware, Nutanix and All Other Linux-Based Hypervisors, Powered by Vali Cyber®, to Safeguard Against Ransomware and Other Vulnerabilities (Graphic: Business Wire) The Rimini Protect AHS solution combines Vali Cyber technology with Rimini Str
Qualcomm Schedules First Quarter Fiscal 2025 Earnings Release and Conference Call22.1.2025 15:00:00 CET | Press Release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its first quarter fiscal 2025 on Wednesday, February 5, 2025, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its first quarter fiscal 2025 results which will be broadcast live on February 5, 2025, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/investor-events/default.aspx. An audio replay will be available at https://investor.qualcomm.com/news-events/investor-events/default.aspx and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international call
Novotech Releases Comprehensive Report on Oncolytic Virus Therapy22.1.2025 14:05:00 CET | Press Release
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122884484/en/ Oncolytic virus therapies utilize genetically modified or naturally occurring viruses to selectively target tumor cells and stimulate immune responses. This dual mechanism is creating new possibilities in oncology and other therapeutic areas. Key Highlights: Global Trial Landscape: Asia-Pacific leads with 40% of OVT clinical trials, followed closely by North America and Europe, refle
Improbable Leverages Improved Financial Profile to Drive Innovation in AI, the Metaverse, and Web3 Through Venture Building22.1.2025 14:00:00 CET | Press Release
Improbable, a venture builder dedicated to growing businesses across AI, the metaverse, and Web3 ecosystems, has capped off a transformative 2024 with the announcement of the profitability threshold achieved in the previous financial year, a change in business model, and significant progress across interconnected ecosystems. Central to its success is the company’s venture-building model, which has proven instrumental in creating businesses and technologies that shape the future of virtual worlds and digital economies. Venture Building: Driving Innovation Across Ecosystems and Building the Open Metaverse Improbable’s venture-building strategy has been key to addressing challenges and unlocking opportunities across frontier ecosystems. In 2024, the company launched several new ventures, including: Kallikor, an AI-powered platform accelerating the adoption of robotics in supply chains. Jitter, transforming Twitch streams into interactive multiplayer games. Chamber, a next-gen platform ble
WEF25: Saudi Foreign Minister Says Middle East Has “Opportunity to Turn a Page” Following Gaza Ceasefire22.1.2025 13:25:00 CET | Press Release
Saudi Arabia’s Minister of Foreign Affairs, His Highness Prince Faisal bin Farhan bin Abdullah, today said the Middle East has an opportunity to shape a prosperous future following the Gaza ceasefire deal which came into effect at the start of the week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121797711/en/ Saudi Arabia’s Minister of Foreign Affairs, His Highness Prince Faisal bin Farhan bin Abdullah, addressed a panel session at the World Economic Forum Annual Meeting 2025 in Davos on ‘Diplomacy amid Disorder’, where he spoke about an opportunity for the region “to turn a page” (Photo: AETOSWire) “We are certainly in a region that is abundant with risk factors. But we are also in a region that has huge potential. Even with a very difficult year behind us, we have shown we can be resilient as a region and we can look to the future, whether it’s the Kingdom, the GCC countries and their ability to stay on track with t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom